Table 2.
Treatment
| All | Success | Indeterminate | Failure | Pa | Pb | |
|---|---|---|---|---|---|---|
| n | 157 | 23 | 80 | 54 | ||
| Any in vitro active drug in first 7 days | ||||||
| aminoglycoside | 76 (48) | 14 (61) | 42 (53) | 20 (37) | 0.0292 | 0.0041 |
| colistin | 27 (17) | 4 (17) | 11 (14) | 12 (22) | 0.3469 | 0.6531 |
| tigecycline | 66 (42) | 8 (35) | 26 (33) | 32 (59) | 0.0047 | 0.0365 |
| SXT | 18 (11) | 2 (9) | 11 (14) | 5 (9) | 0.7801 | 0.9633 |
| fosfomycin | 19 (12) | 2 (9) | 8 (10) | 9 (17) | 0.2168 | 0.2790 |
| Base of regimenc | 0.0269 | 0.0083 | ||||
| aminoglycoside | 76 (48) | 14 (61) | 42 (53) | 20 (37) | ||
| colistin | 23 (15) | 3 (13) | 10 (13) | 10 (19) | ||
| tigecycline | 36 (23) | 3 (13) | 14 (18) | 19 (35) | ||
| other | 22 (14) | 3 (13) | 14 (18) | 5 (9) | ||
| Single in vitro active drug in first 7 daysd | 110 (70) | 16 (70) | 63 (79) | 31 (57) | 0.0500 | |
| aminoglycoside | 47 (30) | 8 (35) | 28 (35) | 11 (20) | 0.2990 | 0.1004 |
| colistin | 11 (7) | 2 (9) | 8 (10) | 1 (2) | 0.2079 | 0.3182 |
| tigecycline | 30 (19) | 3 (13) | 13 (16) | 14 (26) | 0.0148 | 0.0102 |
| SXT | 14 (9) | 2 (9) | 9 (11) | 3 (6) | 0.6664 | 0.9531 |
| fosfomycin | 8 (5) | 1 (4) | 5 (6) | 2 (4) | 0.9444 | 0.9888 |
| >1 in vitro active drug in first 7 dayse | 47 (30) | 7 (30) | 17 (21) | 23 (43) | 0.0500 | 0.0575 |
| aminoglycoside + tigecycline | 17 (11) | 4 (17) | 9 (11) | 4 (7) | — | |
| aminoglycoside + fosfomycin | 7 (4) | 1 (4) | 3 (4) | 3 (6) | — | |
| aminoglycoside + colistin | 2 (1) | 1 (4) | 0 | 1 (2) | — | |
| aminoglycoside + colistin + tigecycline | 2 (1) | 0 | 1 (1) | 1 (2) | — | |
| aminoglycoside + SXT | 1 (1) | 0 | 1 (1) | 0 | — | |
| colistin + tigecycline | 11 (7) | 1 (4) | 2 (3) | 8 (15) | — | |
| colistin + fosfomycin | 1 (1) | 0 | 0 | 1 (2) | — | |
| tigecycline + SXT | 3 (2) | 0 | 1 (1) | 2 (4) | ||
| tigecycline + fosfomycin | 3 (2) | 0 | 0 | 3 (6) | ||
SXT, trimethoprim/sulfamethoxazole.
All data are expressed as n (%), unless otherwise indicated.
aP value indicating the univariate relationship between the variable of interest and the ordinal outcome (success, indeterminate, failure).
bAdjusted for the presence of UTI, critical illness and for receipt of more than one anti-CRKP drug (except for single drug variables and single drug versus multiple drugs, which were adjusted for UTI only).
cBase of regimen was assigned as follows: any regimen that contained an aminoglycoside was deemed aminoglycoside-based; any regimen that contained colistin, but not an aminoglycoside, was deemed colistin-based; and any regimen that contained tigecycline, but not colistin or an aminoglycoside, was deemed tigecycline-based. All other regimens were classified as ‘other’.
dComparisons are made within the single drug group.
eThe group of patients who received more than one drug was compared with those who received a single drug. No analyses were performed on individual combination regimens secondary to small numbers.